why choose us

First received: November 21, 2022

Clinical Trial: ADRB3 Signaling Pathway in Human Adipose Tissue

Study Status: NOT_YET_RECRUITING

Recruit Status: NOT_YET_RECRUITING

Condition: Obesity, Prediabetes

Study Type: INTERVENTIONAL


Official Title: Identifying Responsible Signaling Pathway for Adrenergic Beta-3 Receptor Regulation in Human Subcutaneous White Adipose Tissue

Brief Summary: This study will examine the gene expression of the adrenergic Beta-3 receptor (ADRB3) regulation in human subcutaneous adipose tissue before and after treatment with mirabegron, an ADRB3 agonist.Gene expression will be compared across two groups, lean and obese participants.There will be a total of three study visits: Screening/Eligibility, Pre-Dose Adipose Tissue Biopsy and Post-Dose Adipose Tissue Biopsy.Participants will be given a single dose of 100mg oral mirabegron on the day of the Post-Dose Adipose…

Read more